Merck, Inc.
Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)
- Conditions
- Endometrial Neoplasms
- Interventions
- First Posted Date
- 2021-12-30
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 280
- Registration Number
- NCT05173987
- Locations
- 🇺🇸
Northside Hospital ( Site 0017), Atlanta, Georgia, United States
🇺🇸St. Dominic's Hospital ( Site 0024), Jackson, Mississippi, United States
🇺🇸John Theurer Cancer Center at Hackensack University Medical Center ( Site 0026), Hackensack, New Jersey, United States
Safety, Tolerability, and Immunogenicity of V110 or V114 Co-administered With a Booster Dose of mRNA-1273 in Healthy Adults (V110-911)
- Conditions
- Pneumococcal Infection
- Interventions
- Biological: Placebo for V110Biological: Placebo for V114
- First Posted Date
- 2021-12-15
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 850
- Registration Number
- NCT05158140
- Locations
- 🇺🇸
Valley Clinical Trials Inc. ( Site 0002), Northridge, California, United States
🇵🇷CAIMED Center - Ponce School of Medicine ( Site 0103), Ponce, Puerto Rico
🇺🇸Charlottesville Medical Research Center, LLC ( Site 0008), Charlottesville, Virginia, United States
A Study to Evaluate Zilovertamab Vedotin (MK-2140) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-004)
- Conditions
- Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- Interventions
- Biological: MK-2140 (zilovertamab vedotin)
- First Posted Date
- 2021-12-03
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 140
- Registration Number
- NCT05144841
- Locations
- 🇫🇷
Centre Hospitalier de la Côte Basque ( Site 1002), Bayonne, Aquitaine, France
🇸🇪Skånes Universitetssjukhus Lund ( Site 2100), Lund, Skane Lan, Sweden
🇹🇷Ankara University Hospital Cebeci-hematology ( Site 2300), Ankara, Turkey
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
- Conditions
- Diffuse Large B-Cell LymphomaDLBCL
- Interventions
- Drug: Granulocyte Colony-Stimulating Factor (G-CSF)
- First Posted Date
- 2021-12-01
- Last Posted Date
- 2025-05-29
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 290
- Registration Number
- NCT05139017
- Locations
- 🇹🇷
Dokuz Eylül Üniversitesi-Hematology ( Site 1905), Izmir, Turkey
🇹🇷Ondokuz Mayıs Universitesi ( Site 1907), Samsun, Turkey
🇺🇦MNPE ClinCenter of Oncology,Hematology,Transplantology and Palliative Care of CherkasyRegCouncil ( Site 2000), Cherkasy, Cherkaska Oblast, Ukraine
Evoked Responses as Pharmacodynamic Biomarkers in Healthy and Schizophrenic Participants (MK-4334-007)
- Conditions
- Cognitive Impairment Associated With Schizophrenia
- Interventions
- First Posted Date
- 2021-11-29
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 38
- Registration Number
- NCT05136690
- Locations
- 🇺🇸
Collaborative Neuroscience Research, LLC ( Site 0002), Long Beach, California, United States
🇺🇸Hassman Research Institute Marlton Site ( Site 0001), Marlton, New Jersey, United States
A Study of Islatravir (MK-8591) in Trans and Gender Diverse Participants (MK-8591-035)
- Conditions
- Human Immunodeficiency Virus (HIV) Infections
- Interventions
- First Posted Date
- 2021-11-22
- Last Posted Date
- 2022-10-17
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Registration Number
- NCT05130086
Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribonucleic Acid (mRNA)-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19) Vaccine (V503-076)
- Conditions
- Coronavirus Disease (COVID-19)Papillomavirus Infections
- Interventions
- Biological: 9vHPV VaccineBiological: mRNA-1273 Vaccine
- First Posted Date
- 2021-11-15
- Last Posted Date
- 2025-02-21
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 165
- Registration Number
- NCT05119855
- Locations
- 🇺🇸
West Houston Clinical Research Services ( Site 0078), Houston, Texas, United States
🇺🇸Next Level Urgent Care, LLC ( Site 0099), Houston, Texas, United States
🇺🇸Ark Clinical Research ( Site 0108), Tustin, California, United States
Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65)
- Conditions
- Ovarian CancerCarcinoma, Ovarian EpithelialFallopian Tube Neoplasms
- Interventions
- Other: Placebo for pembrolizumab
- First Posted Date
- 2021-11-10
- Last Posted Date
- 2025-03-07
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 616
- Registration Number
- NCT05116189
- Locations
- 🇺🇸
University of Massachusetts Chan Medical School-Division of Gynecologic Oncology ( Site 0003), Worcester, Massachusetts, United States
🇺🇸John Theurer Cancer Center at Hackensack University Medical Center ( Site 0007), Hackensack, New Jersey, United States
🇨🇦BC Cancer Victoria ( Site 0513), Victoria, British Columbia, Canada
Radiopaque Matrix MK-8591 Implant in Participants at Low-Risk for Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591-043)
- First Posted Date
- 2021-11-10
- Last Posted Date
- 2023-11-24
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Registration Number
- NCT05115838
Ulonivirine (MK-8507) in Participants With Mild or Moderate Hepatic Impairment (MK-8507-014)
- First Posted Date
- 2021-10-26
- Last Posted Date
- 2025-02-18
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 22
- Registration Number
- NCT05093972